Research programme: monoclonal antibody HUI 77-derived cancer therapies - Micromet
Alternative Names: QH2BLatest Information Update: 18 Mar 2008
At a glance
- Originator University of Southern California
- Developer Micromet Inc
- Class Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Collagen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Eye disorders; Solid tumours
Most Recent Events
- 05 May 2006 CancerVax Corporation merged with Micromet AG to form Micromet Inc
- 03 Apr 2006 The US FDA has approved an IND application for D93 to begin phase I trials in solid tumours
- 25 Jul 2005 Preclinical trials in Eye disorders in USA (Parenteral)